These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16118017)

  • 21. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease.
    Wu F; Wang Z; Gu JH; Ge JB; Liang ZQ; Qin ZH
    Neurochem Int; 2013 Sep; 63(3):133-40. PubMed ID: 23714208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease.
    Wang X; Cui G; Yang X; Zhang Z; Shi H; Zu J; Hua F; Shen X
    Brain Res Bull; 2014 Apr; 103():60-5. PubMed ID: 24583079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced advanced model of Parkinson's disease.
    Fernández M; Barcia E; Fernández-Carballido A; Garcia L; Slowing K; Negro S
    Int J Pharm; 2012 Nov; 438(1-2):266-78. PubMed ID: 22985602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
    Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
    Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
    Tapias V; Cannon JR; Greenamyre JT
    J Neurosci Res; 2010 Feb; 88(2):420-7. PubMed ID: 19681169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.
    Alam M; Schmidt WJ
    Behav Brain Res; 2002 Oct; 136(1):317-24. PubMed ID: 12385818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary optimization of a Chinese herbal medicine formula based on the neuroprotective effects in a rat model of rotenone-induced Parkinson's disease.
    Bao XX; Ma HH; Ding H; Li WW; Zhu M
    J Integr Med; 2018 Jul; 16(4):290-296. PubMed ID: 29866613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
    Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
    Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson's disease.
    Khurana N; Gajbhiye A
    Neurotoxicology; 2013 Dec; 39():57-64. PubMed ID: 23994302
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease.
    Verma R; Nehru B
    Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variable effects of chronic subcutaneous administration of rotenone on striatal histology.
    Zhu C; Vourc'h P; Fernagut PO; Fleming SM; Lacan S; Dicarlo CD; Seaman RL; Chesselet MF
    J Comp Neurol; 2004 Oct; 478(4):418-26. PubMed ID: 15384065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of electroacupuncture on proteasomes of substantia nigra in rats with Parkinson's disease].
    Tu Q; Liang Y; Ma J; Wang S; Shen F; Wang Y
    Zhongguo Zhen Jiu; 2015 Apr; 35(4):355-60. PubMed ID: 26054145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The neuroprotective and neurorescue effects of carbamylated erythropoietin Fc fusion protein (CEPO-Fc) in a rat model of Parkinson's disease.
    Thomas Tayra J; Kameda M; Yasuhara T; Agari T; Kadota T; Wang F; Kikuchi Y; Liang H; Shinko A; Wakamori T; Vcelar B; Weik R; Date I
    Brain Res; 2013 Mar; 1502():55-70. PubMed ID: 23380533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycaprolactone-based neurotherapeutic delivery of rasagiline targeting behavioral and biochemical deficits in Parkinson's disease.
    Kanwar N; Bhandari R; Kuhad A; Sinha VR
    Drug Deliv Transl Res; 2019 Oct; 9(5):891-905. PubMed ID: 30877626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
    Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
    Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histopathological and electrophysiological indices of rotenone-evoked dopaminergic toxicity: Neuroprotective effects of acetyl-L-carnitine.
    Sarkar S; Gough B; Raymick J; Beaudoin MA; Ali SF; Virmani A; Binienda ZK
    Neurosci Lett; 2015 Oct; 606():53-9. PubMed ID: 26321151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
    Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
    Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
    Lin CH; Huang JY; Ching CH; Chuang JI
    J Pineal Res; 2008 Mar; 44(2):205-13. PubMed ID: 18289173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone.
    Fleming SM; Zhu C; Fernagut PO; Mehta A; DiCarlo CD; Seaman RL; Chesselet MF
    Exp Neurol; 2004 Jun; 187(2):418-29. PubMed ID: 15144868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.